Volume 16, Number 5—May 2010
Letter
Cross-Reactive Antibodies to Pandemic (H1N1) 2009 Virus, Singapore
Table
Cross-reactive antibody titers to pandemic (H1N1) 2009 and seasonal influenza viruses for 50 persons, Singapore, May–October 2009*
Patient age, y/sex | Laboratory 1 (Singapore General Hospital) |
Laboratory 2 (WHO, Melbourne)+ |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
A/Auckland/1/2009 |
A/Brisbane/59/2007 |
A/Auckland/1/2009 |
A/Brisbane/59/2007 |
|||||||
HI† | MN | HI† | MN | HI‡ | HI† | HI‡ | ||||
45/F | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
52/F | <10 | 10 | 10 | 10 | <10 | 10 | <10 | |||
52/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
52/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/F | <10 | <10 | 20 | 40 | <10 | <10 | 40 | |||
53/F | <10 | <10 | 160 | 80 | <10 | <10 | 160 | |||
53/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/F | <10 | <10 | 160 | 320 | <10 | <10 | 160 | |||
53/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
54/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
54/M | 10 | <10 | 10 | <10 | <10 | 20 | <10 | |||
55/F | <10 | <10 | 10 | <10 | <10 | 10 | <10 | |||
55/F | <10 | <10 | 160 | 40 | <10 | <10 | 160 | |||
55/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
56/F | <10 | <10 | 20 | 10 | <10 | <10 | 10 | |||
56/F | <10 | <10 | 80 | 80 | <10 | 20 | 40 | |||
56/F | <10 | 10 | 10 | 40 | <10 | <10 | 10 | |||
56/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
57/M | 10 | 20 | 40 | 40 | 20 | 20 | <10 | |||
58/M | <10 | <10 | 20 | 20 | <10 | 10 | 20 | |||
58/F | <10 | <10 | 40 | 20 | <10 | <10 | 80 | |||
59/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
59/M | <10 | <10 | 20 | 20 | 20 | 20 | 10 | |||
59/F | <10 | <10 | 40 | 40 | <10 | <10 | 40 | |||
60/M | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
60/M | <10 | <10 | 20 | 10 | <10 | <10 | 20 | |||
60/F | 10 | <10 | 10 | <10 | NR | <10 | <10 | |||
61/F | 10 | <10 | 10 | <10 | <10 | 10 | <10 | |||
61/M | 10 | <10 | 160 | 160 | <10 | <10 | 320 | |||
61/M | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
61/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
62/F | <10 | 20 | 10 | 20 | NR | NR | NR | |||
62/F | 10 | 10 | 80 | 20 | <10 | <10 | 40 | |||
62/F | <10 | <10 | 20 | 10 | <10 | 20 | 40 | |||
62/F | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
63/M | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
63/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
63/M | <10 | <10 | 40 | 20 | <10 | <10 | 20 | |||
63/M | <10 | <10 | 40 | 80 | <10 | <10 | 20 | |||
64/F | 10 | <10 | 20 | 10 | <10 | 10 | 10 | |||
65/F | 10 | <10 | 10 | <10 | <10 | 20 | <10 | |||
66/M | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
68/M | <10 | <10 | 40 | 80 | <10 | <10 | 40 | |||
71/F | 10 | 10 | 10 | 20 | <10 | <10 | <10 | |||
72/F | <10 | 20 | 10 | 20 | 10 | 10 | <10 | |||
75/M | <10 | <10 | 10 | 10 | <10 | 20 | <10 | |||
76/M | <10 | <10 | 40 | 20 | <10 | <10 | 40 | |||
78/F | <10 | 10 | 10 | 20 | <10 | <10 | <10 | |||
82/F | 10 | 10 | 20 | 10 | <10 | 20 | <10 |
*WHO, World Health Organization; HI, hemagglutination inhibition; MN, microneutralization; NR, no results (because of insufficient serum).
†Tested with guinea pig erythrocytes.
‡Tested with turkey erythrocytes.
Page created: December 23, 2010
Page updated: December 23, 2010
Page reviewed: December 23, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.